Veerman GDM - Search Results

1

Analysis of Serious Weight Gain in Patients Using Alectinib for ALK-Positive Lung Cancer.

de Leeuw SP, Pruis MA, Sikkema BJ, Mohseni M, Veerman GDM, Paats MS, Dumoulin DW, Smit EF, Schols AMWJ, Mathijssen RHJ, van Rossum EFC, Dingemans AC. de Leeuw SP, et al. Among authors: veerman gdm. J Thorac Oncol. 2023 Aug;18(8):1017-1030. doi: 10.1016/j.jtho.2023.03.020. Epub 2023 Mar 29. J Thorac Oncol. 2023. PMID: 37001858 Free article.

2

Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.

Ruiz van Haperen VW, Veerman G, Eriksson S, Stegmann AP, Peters GJ. Ruiz van Haperen VW, et al. Semin Oncol. 1995 Aug;22(4 Suppl 11):35-41. Semin Oncol. 1995. PMID: 7481843

3

Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines.

Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Bergman AM, et al. Adv Exp Med Biol. 1994;370:139-43. doi: 10.1007/978-1-4615-2584-4_32. Adv Exp Med Biol. 1994. PMID: 7660877 No abstract available.

4

In vitro antiproliferative effects, toxicity profiles in vivo in mice and antitumour activity in tumour-bearing mice of five organotin compounds.

Gielen M, Willem R, Bouhdid A, De Vos D, Kuiper CM, Veerman G, Peters GJ. Gielen M, et al. In Vivo. 1995 Jan-Feb;9(1):59-63. In Vivo. 1995. PMID: 7669950

5

Augmentation of 1-beta-D-arabinofuranosylcytosine (Ara-C) cytotoxicity in leukaemia cells by co-administration with antisignalling drugs.

Freund A, Boos J, Harkin S, Schultze-Mosgau M, Veerman G, Peters GJ, Gescher A. Freund A, et al. Eur J Cancer. 1998 May;34(6):895-901. doi: 10.1016/s0959-8049(97)10149-6. Eur J Cancer. 1998. PMID: 9797704

6

Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.

van Moorsel CJ, Bergman AM, Veerman G, Voorn DA, Ruiz van Haperen VW, Kroep JR, Pinedo HM, Peters GJ. van Moorsel CJ, et al. Biochim Biophys Acta. 2000 Mar 6;1474(1):5-12. doi: 10.1016/s0304-4165(99)00209-3. Biochim Biophys Acta. 2000. PMID: 10699484

7

Interaction between cisplatin and gemcitabine in vitro and in vivo.

Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ. Peters GJ, et al. Semin Oncol. 1995 Aug;22(4 Suppl 11):72-9. Semin Oncol. 1995. PMID: 7481849

8

Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).

Kroep JR, van Moorsel CJ, Veerman G, Voorn DA, Schultz RM, Worzalla JF, Tanzer LR, Merriman RL, Pinedo HM, Peters GJ. Kroep JR, et al. Adv Exp Med Biol. 1998;431:657-60. doi: 10.1007/978-1-4615-5381-6_127. Adv Exp Med Biol. 1998. PMID: 9598147 No abstract available.

9

In vitro antiproliferative effects, toxicity profiles in vivo in mice and antitumour activity in tumour-bearing mice of four diorganotin compounds.

Gielen M, Willem R, Bouhdid A, Devos D, Kuiper C, Veerman G, Peters G. Gielen M, et al. Oncol Rep. 1996 May;3(3):583-7. doi: 10.3892/or.3.3.583. Oncol Rep. 1996. PMID: 21594418

10

Preclinical combination therapy with gemcitabine and mechanisms of resistance.

Peters GJ, Ruiz van Haperen VW, Bergman AM, Veerman G, Smitskamp-Wilms E, van Moorsel CJ, Kuiper CM, Braakhuis BJ. Peters GJ, et al. Semin Oncol. 1996 Oct;23(5 Suppl 10):16-24. Semin Oncol. 1996. PMID: 8893877 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

60 results

Search Page

Filters